4basebio Uk Societas chart

Last update: 2022-12-30
Key statistics and financials
Revenue per share 0.03
Dividend & YieldN/A£ (N/A)
Beta N/A
Market capitalization 67.75M
Operating cash flow -3.54M
ESG Scores unknown

Company description

4basebio PLC engages in the design, development, manufacturing, and supply of synthetic DNA and RNA products, and targeted non-viral vector solutions in the United States, Europe, and internationally. The company provides research kits, bulk enzymes, and other products, as well as licensing services; and AVV manufacturing services. It serves biotech, pharma, and contract development and manufacturing organization customers. The company was formerly known as 4basebio UK Societas and changed its name to 4basebio PLC in July 2021. 4basebio PLC was incorporated in 2020 and is based in Cambridge, United Kingdom.

Sector: Healthcare - Industry: Biotechnology

Financial Ratios
Quick Ratio18.92
Working Capital-0.05
Return On Equity-0.05
Debt To Equity0.08
Fixed Asset Ratio0.01
Fixed Interest Cover-6.62

Financial data

Financial Statements

Cashflow Statement 2019-12-31 2020-12-31 2021-12-31
Change To Liabilities -668k -876k 615k
Total Cashflows From Investing Activities -812k 1.45M -1.51M
Net Borrowings 2.37M -1.08M -391k
Total Cash From Financing Activities 1.95M 14.43M -467k
Change To Operating Activities
Issuance Of Stock 15.63M 15.63M
Net Income -1.69M -719k -3.23M
Change In Cash 48k 14.92M -5.42M
Effect Of Exchange Rate -16k 70k -696k
Total Cash From Operating Activities -1.08M -1.02M -2.74M
Depreciation 216k 89k 251k
Change To Account Receivables 464k 91k -126k
Other Cashflows From Financing Activities -420k -116k -76k
Change To Netincome -368k 229k -280k
Capital Expenditures -12k -351k -884k

Income Statement 2019-12-31 2020-12-31 2021-12-31
Research Development 1.02M 343k 1.62M
Income Before Tax -2.12M -716k -3.64M
Net Income -1.69M -719k -3.23M
Selling General Administrative 1.42M 657k 1.86M
Gross Profit -112k 274k 269k
Ebit -1.66M -622k -3.53M
Operating Income -1.66M -622k -3.53M
Interest Expense -436k -94k -113k
Income Tax Expense -424k 3k -405k
Total Revenue 808k 462k 338k
Cost Of Revenue 920k 188k 69k
Total Other Income ExpenseNet -460k -94k -113k
Net Income From Continuing Ops -1.69M -719k -3.23M
Net Income Applicable To Common Shares -1.69M -719k -3.23M

Balance Sheet Statement 2019-12-31 2020-12-31 2021-12-31
Total Liabilities 3.04M 2.35M 3.01M
Total Stockholder Equity -1.89M 15.46M 11.7M
Other Current Liabilities 10k 1k 1k
Total Assets 1.16M 17.81M 14.7M
Common Stock 6.36M 11.13M 11.13M
Other Current Assets 40k 59k 68k
Retained Earnings -9.62M -10.34M -13.57M
Treasury Stock 1.37M 13.96M 13.43M
Cash 80k 15M 9.59M
Total Current Liabilities 566k 813k 1.52M
Other Stockholder Equity 1.37M 13.96M 13.43M
Property, Plant, and Equipment 78k 1.48M 2.76M
Total Current Assets 598k 15.51M 10.64M
Net Tangible Assets -1.96M 15.36M 11.53M
Net Receivables 180k 102k 604k
Accounts Payable 101k 96k 353k


Insider Transactions

Here are the insider transactions of stock shares related to 4basebio Uk Societas:

Filer Name Transaction Text Ownership Date Filer Relation Shares
Lanckriet (Heikki)D2022-07-12
Roth (David John)Bought at price 5.31 per share.D2022-06-165k
Roth (David John)Bought at price 5.86 per share.D2022-05-124k
Lanckriet (Heikki)Bought at price 5.73 per share.D2022-05-123k
Lanckriet (Heikki)Bought at price 6.17 per share.D2022-05-09500
Sparta AGD2022-05-06
Lanckriet (Heikki)D2022-05-06
4bb AGD2022-05-06
Deutsche Balaton AktiengesellschaftD2022-05-06
Fernandez (Joseph Manuel)D2022-05-06
Delphi Unternehmensberatung AktiengesellschaftD2022-05-06
Lanckriet (Heikki)Bought at price 8.59 per share.D2021-12-201k
Lanckriet (Heikki)Bought at price 8.61 per share.D2021-12-171.5k
Lanckriet (Heikki)Bought at price 8.62 per share.D2021-12-133k
Lanckriet (Heikki)Bought at price 6.43 per share.D2021-07-013.45k
Fernandez (Joseph Manuel)D2021-06-02
Lanckriet (Heikki)D2021-06-02
Deutsche Balaton AktiengesellschaftD2021-06-02
4bb AGD2021-06-02
Lanckriet (Heikki)Bought at price 4.83 per share.D2021-02-253k
Deutsche Balaton AktiengesellschaftD2021-02-17494
4bb AGD2021-02-17
Sparta AGD2021-02-17393
Sparta AGD2021-02-17
4bb AGD2021-02-17
Roth (David John)D2021-02-17
Plaggemars (Hansjoerg)D2021-02-17
Mc-Carthy (Timothy Paul)D2021-02-17
Delphi Unternehmensberatung AktiengesellschaftD2021-02-17
Delphi Unternehmensberatung AktiengesellschaftD2021-02-17
Lanckriet (Heikki)D2021-02-17
Fernandez (Joseph Manuel)D2021-02-17
Deutsche Balaton AktiengesellschaftD2021-02-17

Insider transaction explanations

Insider buying is the legal purchase of shares by a senior executive or director of a company. "Filer Name" corresponds to the name of the stock buyer or seller. "Transaction Text" describes the transaction. "Ownership" gives information about the transaction type. "Date" is the reported transaction date. "Filer Relation" gives the role of the insider in the company. "Shares" is the value of the transaction. You will find the complete description of the General Transaction Codes on the SEC dedicated page


Investment strategy backtesting

These are the result of three automatic investment systems applied to 4basebio Uk Societas. You will find the performance of an systematic investment system, a momentum strategy, and a buy the dip trading strategy.


Systematic investment results on 4basebio Uk Societas

Here is the result of two systematic investment strategies applied to 4basebio Uk Societas. The first strategy automatically buys the first day of the month, and the second strategy buys the fifteenth day of the month.

Systematic investment equity curve on 4basebio Uk Societas

The following chart shows the equity curve of the two systematic investment strategies applied to 4basebio Uk Societas:

4basebio Uk Societas automated entries

The systematic investment strategy that buys the first day of the month would give a performance of 6.11% on the backtest period.

Performance at glance

Performance

6.11 %

Latent gain

40.0 £

Invested capital

655.0 £

Annualized return

8.26 %
Build your Trading System
Automated Trading using Prorealtime ebook

Momentum strategy results on 4basebio Uk Societas

This is the result of two momentum investment strategies applied to 4basebio Uk Societas. The first strategy uses a momentum signal calculated on one quarter, and the second uses a momentum signal calculated on two quarters.

Momentum entry openings on 4basebio Uk Societas

The following chart shows all the entries opened by the momentum investment system on 4basebio Uk Societas:

4basebio Uk Societas momentum entries
  • The first momentum investment strategy would give 34.95% of return on 4basebio Uk Societas. That represents 360.0£ of latent gain with 1030.0£ of employed capital.
  • The second momentum investment strategy would give 6.11% of return on 4basebio Uk Societas. That represents 40.0£ of latent gain with 655.0£ of employed capital.
Performance at glance (1Q Momentum)

Performance

34.95 %

Latent gain

360.0 £

Invested capital

1030.0 £

Annualized return

-0.0 %
Performance at glance (2Q Momentum)

Performance

6.11 %

Latent gain

40.0 £

Invested capital

655.0 £

Annualized return

23.5 %

Momentum equity curve on 4basebio Uk Societas

The following chart shows the equity curve of the two momentum strategies applied to 4basebio Uk Societas:

4basebio Uk Societas momentum equity

Note: the dividends potentially given by 4basebio Uk Societas are not integrated into the calculation of the equity curve neither the performance of the strategy. The integration of the dividends will be available soon.


Employed capital on 4basebio Uk Societas

The following chart shows the employed capital evolution of the two momentum strategies on 4basebio Uk Societas since the beginning:

4basebio Uk Societas

Note: the algorithm buys for a maximum of 250$ per entry. If the stock price is greater than 250£, the system buys only one stock per entry. The investment system stops automatically when the financial exposure reaches 10000£.


Buy the dip strategy result on 4basebio Uk Societas

Buy the dip entry openings on 4basebio Uk Societas

4basebio Uk Societas

The performance achieved by the robo-advisor on 4basebio Uk Societas is 0%. That represents 0.0$ of latent gain with 0.0£ of employed capital. The following chart shows 4basebio Uk Societas stock price with all the entries opened by the automated investment system.

Note: The blue line represents the weekly stock price of 4basebio Uk Societas, and the green triangles represent the entry openings. The artificall robo-advisor needs at least 100 weeks of trading history to work.

Performance at glance

Performance

0 %

Latent gain

0.0 £

Invested capital

0.0 £

Annualized return

-0.0 %

Equity curve of the strategy applied to 4basebio Uk Societas

The following chart shows the result of the investment strategy applied to 4basebio Uk Societas:

4basebio Uk Societas

Note: the dividends potentially given by 4basebio Uk Societas are not integrated into the calculation of the equity curve neither the performance of the strategy. The integration of the dividends will be available soon.


Employed capital on 4basebio Uk Societas

The following chart shows the employed capital evolution since the beginning of the investment strategy on 4basebio Uk Societas:

4basebio Uk Societas

Note: the algorithm buys for a maximum of 250$ per entry. If the stock price is greater than 250$, the system buys only one stock per entry. The investment system stops automatically when the financial exposure reaches 10000$.


Investment strategies comparison on 4basebio Uk Societas

In this section, I will compare the three previous investment strategies applied to 4basebio Uk Societas.

Equity curve comparison on 4basebio Uk Societas

The following chart shows the equity curve of the artificall advisor, the trend folowing and the automatic investment strategies:

4basebio Uk Societas investment strategy comparison

Employed capital comparison on 4basebio Uk Societas

4basebio Uk Societas investment comparison

Performance comparison on 4basebio Uk Societas

Strategy Latent Profit Growth Employed capital CAGR
Automatic investment 6.11% 40.0£ 655.0£ 8.26%
Momentum 1 quarter 34.95% 360.0£ 1030.0£ 69.9%
Momentum 2 quarters 6.11% 40.0£ 655.0£ 23.5%
Non-directional 0% 0.0£ 0.0£ -0.0%
Annualized return comparison

Automatic investment

8.26 %

Momentum 1Q

23.5 %

Momentum 2Q

23.5 %

Non-directional

-0.0 %

Correlated stocks

Here are the most positively and negatively correlated stocks with 4basebio Uk Societas:

Positive correlations

Most correlated stocks this year


Most correlated stocks last 3 months

Negative correlation

Most negatively correlated stocks this year


Most negatively correlated stocks last 3 months

Note: The algorithm computes the probability of correlation between 4basebio Uk Societas and the other stocks. There may be false positives or some missing correlated stocks. If the price of 4basebio Uk Societas does not vary for 36 weeks, the correlation calculation result will be wrong.


Company information

Company name 4basebio Uk Societas
Country United Kingdom
City Cambridge
Address 25 Norman Way
Phone 44 1223 967 943
Website www.4basebio.com
FullTime employees 51
Industry Biotechnology
Sector Healthcare
Exchange XLON
Ticker 4BB.XLON
Market www.londonstockexchange.com

4basebio Uk Societas ESG Scores

Environment scores

Environment ESG Factors Scores
Environment Score 0
Peer Environment Performance unknown
Environment Percentile unknown
Palm Oil unknown
Nuclear unknown
Fur Leather unknown
GMO unknown
Coal unknown
Pesticides unknown
Animal Testing unknown

Social scores

Social ESG Factors Scores
Social Score 0
Peer Social Performance unknown
Social Percentile unknown
Highest Controversy unknown
Peer Highest Controversy Performance unknown
Adult unknown
Gambling unknown
Alcoholic unknown
Tobacco unknown
Catholic unknown
Controversial Weapons unknown
Small Arms unknown
Military Contract unknown
Peer Count unknown

Related Controversy:


Governance scores

Governance ESG Factors Scores
Governance Score 0
Peer Governance Performance unknown
Governance Percentile unknown

ESG at glance
Total ESG Scores: unknown
Environment Score: 0
Social Score: 0
Governance Score: 0

ESG Performance: unknown

Peer Group: unknown

Peer Esg Score Performance: unknown

Rating Year: unknown

Rating Month: unknown

Max Age: unknown

Percentile: unknown